Bioptix, Inc. (NASDAQ:BIOP) Files An 8-K Other EventsItem 8.01 Other Events.
Bioptix, Inc. (NASDAQ:BIOP) Files An 8-K Other Events
As previously disclosed in the Current Report on Form 8-K filed with the Commission on December 2, 2016, effective as of November 30, 2016, Bioptix, Inc., formerly known as Venaxis, Inc. (the “Company”) changed its name from “Venaxis, Inc.” to “Bioptix, Inc.” by amending its Articles of Incorporation, as amended.
The Company’s name change became effective with the Financial Industry Regulatory Authority, Inc. (“FINRA”) on December 12, 2016, and the Company’s common stock began quotation on the Nasdaq Capital Market under the new name and a new trading symbol, “BIOP.” In connection with the new trading symbol, the Company has been assigned a new CUSIP number of 09074N101.
On December 8, 2016, the Company issued a press release announcing the name change and trading symbol change. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
For shareholders holding their shares of Company stock in certificated form, replacement of current stock certificates of the Company will not be necessary as a result of the Company’s name change and change in trading symbol, however, shareholders may submit their stock certificates to the Company’s transfer agent, Corporate Stock Transfer, Inc., for new certificates in accordance with the share certification instruction letter attached as Exhibit 99.2 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Press release dated December 8, 2016
99.2 Share Certificate Instruction Letter
About Bioptix, Inc. (NASDAQ:BIOP)
Bioptix, Inc., formerly Venaxis, Inc., provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions. The Company’s line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. Its SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug will be efficacious in humans and at what dose a drug should be administered. Its technology is an ultra-sensitive detection platform. The design of its SPR spectrometers allows discrete areas within the sample cell to be interrogated simultaneously by use of photo-diode arrays aligned to the reflected beam from the sample cell. Its biosensors provide information on kinetic processes (association and dissociation), binding affinities, analyte concentrations and real-time molecule detection. The Company offers 404pi Enhanced SPR System, which enables real-time detection of biomolecular interactions.
Bioptix, Inc., formerly Venaxis, Inc., provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions. The Company’s line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. Its SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug will be efficacious in humans and at what dose a drug should be administered. Its technology is an ultra-sensitive detection platform. The design of its SPR spectrometers allows discrete areas within the sample cell to be interrogated simultaneously by use of photo-diode arrays aligned to the reflected beam from the sample cell. Its biosensors provide information on kinetic processes (association and dissociation), binding affinities, analyte concentrations and real-time molecule detection. The Company offers 404pi Enhanced SPR System, which enables real-time detection of biomolecular interactions.
